-- Beijing Wantai Biological Pharmacy Enterprise (SHA:603392) swung to an attributable loss of 398.3 million yuan in 2025 from an attributable profit of 106.2 million yuan in 2024, according to a Tuesday filing with the Shanghai bourse.
The drug manufacturer logged a loss per share of 0.31 yuan compared with earnings per share of 0.08 yuan in the previous year.
Operating income declined 19% year over year to 1.82 billion yuan from 2.25 billion yuan.
Shares decreased 4% during morning trading on Tuesday.